Scalp psoriasis is a chronic inflammatory condition affecting the scalp's epidermis and dermis, distinguishable from simple dandruff by its persistent inflammation, well-demarcated plaques, and resistance to standard antifungal or cosmetic treatments. Unlike seborrheic dermatitis, which causes yellowish, greasy scales, scalp psoriasis presents with thick, silvery-white scales frequently accompanied by bleeding when removed, pruritus, and potential hair loss.

Pathophysiology and Clinical Presentation

Scalp psoriasis involves dysregulated T-cell mediated immunity, with overactivation of Th17 cells producing IL-17 and IL-22, alongside TNF-alpha and IL-23 signaling pathways. This leads to accelerated keratinocyte proliferation and differentiation. The scalp's unique microenvironment—warm, moist, and friction-prone—creates an optimal setting for inflammatory cascade amplification.

Clinically, patients present with erythematous, scaling plaques with sharp demarcation. Disease severity ranges from mild (confined to the hairline) to severe (widespread involvement with temporary alopecia). Associated symptoms include significant pruritus, pain with scale manipulation, and potential secondary bacterial colonization from scratching. Approximately 50-80% of patients with psoriasis experience scalp involvement during their lifetime, with 7% having scalp-only disease.

Diagnostic Approach

Diagnosis is primarily clinical, based on characteristic morphology and distribution. Dermoscopy reveals regular vascular patterns with elongated capillaries in dilated dermal papillae. Histopathology, when needed for atypical cases, shows acanthosis, parakeratosis, thinning of the suprapapillary epidermis, elongation of the rete ridges, and papillary dermal edema with superficial perivascular lymphocytic infiltrates. The Auspitz sign (pinpoint bleeding after scale removal) and Koebner phenomenon (lesions appearing at trauma sites) support diagnosis.

Differential diagnoses include seborrheic dermatitis, contact dermatitis, atopic dermatitis, tinea capitis, and lichen planus. Scalp biopsy may be necessary when diagnosis remains unclear despite clinical evaluation.

Medical Management

Topical Therapies: Topical corticosteroids remain first-line agents. Class III-IV potency steroids (betamethasone dipropionate 0.05%, clobetasol propionate 0.05%) applied for 2-4 weeks yield 60-75% improvement. Fluticasone propionate 0.05% lotion is well-tolerated with twice-daily application. Steroid-sparing alternatives include topical calcineurin inhibitors (tacrolimus 0.1% ointment), though scalp penetration is variable. Salicylic acid 3-6% facilitates steroid penetration and provides mild keratolytic benefit. Tar-based shampoos (2-10% coal tar) offer modest efficacy as monotherapy but serve better as adjuncts.

Systemic Therapies: Moderate-to-severe scalp psoriasis refractory to topical therapy requires systemic intervention. Methotrexate 10-25 mg weekly (oral or subcutaneous) shows 50-70% PASI75 response rates within 12 weeks. Acitretin 25-50 mg daily achieves approximately 45% PASI50 response but requires strict contraception due to teratogenicity. TNF-alpha inhibitors (etanercept 50 mg weekly, adalimumab 40 mg every other week) demonstrate 60-85% PASI75 response within 12-16 weeks. IL-23 inhibitors, particularly risankizumab (150 mg at weeks 0, 4, 8, then every 12 weeks), show superior efficacy with 75-90% PASI90 achievement. IL-17 inhibitors (secukinumab 300 mg weekly × 4, then monthly; ixekizumab 80 mg weeks 0-4, then every 2 weeks) provide rapid clearance within 2-4 weeks.

Hair Loss Considerations

Psoriatic alopecia occurs through inflammatory destruction of hair follicles and mechanical trauma from scratching. Temporary anagen effluvium is most common, with hair typically regaining normal shedding patterns within 3-6 months of inflammation control. Hair-protective practices include avoiding harsh scratching, using soft-bristled brushes, minimizing heat styling, and treating underlying inflammation aggressively.

Treatment Response Monitoring

Assessment occurs at 4-6 week intervals using the Physician Global Assessment (PGA) and body surface area (BSA) involvement percentage. PASI (Psoriasis Area Severity Index) scoring combines area coverage (0-4) with erythema, infiltration, and desquamation severity (0-4). Response definitions: PASI50 (≥50% improvement), PASI75 (≥75%), and PASI90 (≥90%) guide escalation decisions.

FAQ

Q: Can scalp psoriasis progress to involve other body areas?
A: Yes. Approximately 20-30% of patients with initial scalp-only disease develop additional body site involvement within 5 years. However, many patients maintain scalp-only disease indefinitely.

Q: Is scalp psoriasis contagious?
A: No. Psoriasis is an autoimmune condition with genetic predisposition; it cannot transmit through contact, sharing combs, or other personal items.

Q: Will my hair grow back after scalp psoriasis treatment?
A: Most hair loss is temporary (anagen effluvium). Once inflammation resolves with appropriate therapy, hair regrowth typically occurs within 3-6 months. Permanent scarring alopecia is rare unless severe secondary infection occurs.

Q: How quickly do TNF-inhibitors work on scalp psoriasis?
A: Initial improvement appears within 2-4 weeks, with maximal response at 12-16 weeks. IL-17 and IL-23 inhibitors show faster response, often within 2 weeks.

References

  1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in the United States: results from the National Health and Nutrition Examination Survey. J Am Acad Dermatol. 2009;60(2):218-224.
  2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315.
  3. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):18-25.
  4. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
  5. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.
  6. Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2012;10(3):S1-S95.
  7. Segaert S, Dilme B, Soto-Araya M, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2018;78(4):697-707.
  8. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.
  9. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.